A client with irritable bowel syndrome with diarrhea reports… | MyMerci
Adverse Effects/Contraindications/Interactions PPT
Question

A client with irritable bowel syndrome with diarrhea reports a prior cholecystectomy and receives an eluxadoline prescription. Which action is best?

Explanation
Eluxadoline is contraindicated in clients without a gallbladder because serious and fatal pancreatitis and sphincter of Oddi spasm have occurred, sometimes after 1 or 2 doses.
Next question on this topicA nurse is reviewing the morning lab results for an adult client receiving warfarin for at…

In-depth explanation

Quick answer
Block eluxadoline exposure after cholecystectomy.

Why this is correct
The safety screen occurs before the first dose. Waiting for symptoms exposes the client to a known contraindication.

Easy analogy or mental picture
Use a closed medication-safety loop: identify the exposure, connect the new findings, interrupt further harm, support physiology, and verify the response over time.

Memory hook
Exposure, interaction, toxicity pattern, immediate action, serial reassessment.

NCLEX decision rule
Choose the action that reduces the most immediate medication-related risk while preserving monitoring and escalation.

Why the other choices are wrong
Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic process active.
References
1DailyMed: VIBERZI (eluxadoline)Contraindication without a gallbladder and risk of pancreatitis or sphincter of Oddi spasm

Clinical scenario

Medication safety review
Verify the indication, route, interacting medicines, current respiratory and gastrointestinal findings, authorized action, and measurable follow-up.
Browse all questions No login required

Master the NCLEX-RN with MyMerci

Thousands of NCLEX-style questions with detailed rationale — in your language. Track your progress and study smarter.

Start for free
Read in another language: English한국어日本語繁體中文Tiếng Việt

For study reference only. Always follow current clinical guidelines and your institution’s protocols.